Form 8-K - Current report:
SEC Accession No. 0001372514-25-000045
Filing Date
2025-05-09
Accepted
2025-05-09 07:02:08
Documents
15
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kprx-20250509.htm   iXBRL 8-K 26005
2 EX-99.1 ex991-pressreleasemarch312.htm EX-99.1 88365
6 KIORA LOGO kprx-20250509_g1.jpg GRAPHIC 348944
  Complete submission text file 0001372514-25-000045.txt   1090489

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kprx-20250509.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kprx-20250509_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kprx-20250509_pre.xml EX-101.PRE 13058
17 EXTRACTED XBRL INSTANCE DOCUMENT kprx-20250509_htm.xml XML 2814
Mailing Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024
Business Address 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA 92024 781-788-8869
KIORA PHARMACEUTICALS INC (Filer) CIK: 0001372514 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 25928324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)